Merck Sharp & Dohme LLC and Otsuka Pharmaceutical Co. Ltd. have patented cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the treatment of cancer.
Vanderbilt University has synthesized metabotropic glutamate (mGlu2) receptor negative allosteric modulators reported to be useful for the treatment of depression, anxiety, Alzheimer's disease, autism spectrum, obsessive compulsive and cognitive disorders.
Researchers at the University North Carolina at Chapel Hill and University of Florida have divulged triazoles acting as κ-opioid receptor agonists reported to be useful for the treatment of pain, pruritus, depression, inflammation and more.
The U.S. Court of Appeals for the Federal Circuit remanded a patent case to district court after finding that a patent applicant need not invoke identical terminology when describing a central feature of a catheter technology across multiple patents.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented indazole compounds acting as membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
Chong Kun Dang Pharmaceutical Corp. has disclosed 1,3,4-oxadiazole-containing compounds acting as histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of prion diseases, asthma, psoriasis, inflammatory bowel disease, autosomal dominant polycystic kidney, stroke, Charcot-Marie-Tooth disease and uveitis, among others.
Reglagene Inc. has prepared and tested compounds reported to be useful for the treatment of cancer, familial Mediterranean fever, gout and nail fungal infection.
Merck Sharp & Dohme LLC has identified compounds targeting α-synuclein (ASYN; NACP) acting as positron emission tomography agents reported to be useful for the diagnosis of Parkinson’s disease.
The U.S. Court of Appeals for the Federal Circuit reined in a district court that invalidated three claims in an Astellas Pharma Inc. patent protecting bladder drug Myrbetriq (mirabegron) based on a issue that was never argued.
RSS
